Arca Biopharma | ABIO - Selling And Administration Expenses


Arca Biopharma reported $2.23M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.72B 134M Jun/2026
Arca Biopharma USD 2.23M 1.08M Dec/2025
Biogen USD 709.7M 155.4M Jun/2026
Brainstorm Cell Therapeutics USD 1.21M 178K Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 104.4M 499K Jun/2026
Daiichi Sankyo JPY 249.96B 21.73B Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Grifols EUR 320.45M 12.65M Dec/2025
Laboratory Of America USD 577.2M 26.2M Jun/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Otsuka Holdings JPY 274.44B 14.95B Jun/2026
Pfizer USD 3.41B 496M Jun/2026
United Therapeutics USD 206.7M 50.1M Jun/2026